Literature DB >> 7752003

Permanent heterotopic ossification at the injection site after diphtheria-tetanus-pertussis immunizations in children who have fibrodysplasia ossificans progressiva.

T F Lanchoney1, R B Cohen, D M Rocke, M A Zasloff, F S Kaplan.   

Abstract

In patients who have fibrodysplasia ossificans progressiva, routine childhood diphtheria-tetanus-pertussis immunizations administered by intramuscular injection caused a significant risk of permanent heterotopic ossification at the site of injection (p < 10(-8)), whereas measles-mumps-rubella immunizations administered by subcutaneous injection posed no significant risk. Intramuscular injections should be avoided, if possible, once a diagnosis of fibrodysplasia ossificans progressiva has been established.

Entities:  

Mesh：

Substances：

Year:  1995        PMID： 7752003     DOI： 10.1016/s0022-3476(95)70408-6

Source DB:  PubMed          Journal:  J Pediatr        ISSN： 0022-3476            Impact factor:   4.406


  35 in total

1.  Fibrodysplasia ossificans progressiva: a human genetic disorder of extraskeletal bone formation, or--how does one tissue become another?

Authors:  Eileen M Shore
Journal:  Wiley Interdiscip Rev Dev Biol       Date:  2012 Jan-Feb       Impact factor: 5.814

2.  Chin-on-chest deformity in patients with fibrodysplasia ossificans progressiva. A case series.

Authors:  Ryan E Moore; John P Dormans; Denis S Drummond; Eileen M Shore; Frederick S Kaplan; Joshua D Auerbach
Journal:  J Bone Joint Surg Am       Date:  2009-06       Impact factor: 5.284

Review 3.  The immunological contribution to heterotopic ossification disorders.

Authors:  Michael R Convente; Haitao Wang; Robert J Pignolo; Frederick S Kaplan; Eileen M Shore
Journal:  Curr Osteoporos Rep       Date:  2015-04       Impact factor: 5.096

4.  Myositis ossificans in children: a review.

Authors:  N K Sferopoulos; R Kotakidou; A S Petropoulos
Journal:  Eur J Orthop Surg Traumatol       Date:  2017-03-09

5.  Fibrodysplasia ossificans progressiva (FOP): watch the great toes!

Authors:  Mutlu Kartal-Kaess; Eileen M Shore; Meiqi Xu; Ludwig Schwering; Markus Uhl; Rudolf Korinthenberg; Charlotte Niemeyer; Frederick S Kaplan; Melchior Lauten
Journal:  Eur J Pediatr       Date:  2010-06-26       Impact factor: 3.183

6.  De novo 617G-A nucleotide mutation in the ACVR1 gene in a Taiwanese patient with fibrodysplasia ossificans progressiva.

Authors:  Gau-Tyan Lin; Hsueh-Wei Chang; Chih-Shan Liu; Peng-Ju Huang; Hsien-Chung Wang; Yuh-Min Cheng
Journal:  J Hum Genet       Date:  2006-11-01       Impact factor: 3.172

7.  Early diagnosis of fibrodysplasia ossificans progressiva.

Authors:  Frederick S Kaplan; Meiqi Xu; David L Glaser; Felicity Collins; Michael Connor; Joseph Kitterman; David Sillence; Elaine Zackai; Vardit Ravitsky; Michael Zasloff; Arupa Ganguly; Eileen M Shore
Journal:  Pediatrics       Date:  2008-05       Impact factor: 7.124

8.  PET/CT of fibrodysplasia ossificans progressiva.

Authors:  Robert Kulwin; Larry A Binkovitz
Journal:  Pediatr Radiol       Date:  2009-05-15

9.  When one skeleton is enough: approaches and strategies for the treatment of fibrodysplasia ossificans progressiva (FOP).

Authors:  Frederick S Kaplan; Jay Groppe; Eileen M Shore
Journal:  Drug Discov Today Ther Strateg       Date:  2008

10.  Constitutively activated ALK2 and increased SMAD1/5 cooperatively induce bone morphogenetic protein signaling in fibrodysplasia ossificans progressiva.

Authors:  Toru Fukuda; Masakazu Kohda; Kazuhiro Kanomata; Junya Nojima; Atsushi Nakamura; Jyunji Kamizono; Yasuo Noguchi; Kiyofumi Iwakiri; Takeo Kondo; Junichi Kurose; Ken-ichi Endo; Takeshi Awakura; Junichi Fukushi; Yasuharu Nakashima; Tomohiro Chiyonobu; Akira Kawara; Yoshihiro Nishida; Ikuo Wada; Masumi Akita; Tetsuo Komori; Konosuke Nakayama; Akira Nanba; Yuichi Maruki; Tetsuya Yoda; Hiroshi Tomoda; Paul B Yu; Eileen M Shore; Frederick S Kaplan; Kohei Miyazono; Masaru Matsuoka; Kenji Ikebuchi; Akira Ohtake; Hiromi Oda; Eijiro Jimi; Ichiro Owan; Yasushi Okazaki; Takenobu Katagiri
Journal:  J Biol Chem       Date:  2008-08-06       Impact factor: 5.157
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.